AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Xenon Pharmaceuticals Inc. (NASDAQ:XENE) achieved positive topline results from phase-2b clinical trials of‘XEN1101’ for treating focal epilepsy.
- OpGen, Inc. (NASDAQ:OPGN) got 510(k) received FDA clearance to market Acuitas® AMR Gene Panel; it plans a commercial launch in the US this year.
- Xenon stock jumped over 100%, and OpGen stock rose nearly 7% at the market close on Monday.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) stock skyrocketed by 102.56%, while OpGen, Inc. (NASDAQ:OPGN) stock rose 6.52% at the market close on Monday.
The XENE stock was priced at US$31.60, and OpGen, Inc. traded at US$2.94 at 4:00 pm ET.
Here are some recent developments of the two companies.
Xenon Pharmaceuticals Inc.
Xenon broke its 52-week highest price on Monday after closing at a 100% up. Its trading volume was around 62,258,747. The stock rally comes after the company announced positive topline results from the phase-2b clinical trials of ‘XEN1101’ for treating focal epilepsy.
The British Columbia-based biopharmaceutical company develops therapeutics for neurological disorders. It has a market capitalization of US$1.2 billion. The company brought IPO in 2014.
The stock logged a new 52-week high of US$31.60, while the lowest remained at US$9.32. On Oct 1, it closed at US$15.6, with a trading volume of 295,322. It gave a YTD return of 104.81%.
Also Read: Which companies are helping to remove carbon from the air?
The company posted a net loss of US$21.59 million or US$0.51 per share diluted for the June quarter of 2021 compared to a net loss of US$0.170 million for the previous year’s June quarter. The revenue was US$2.2 million against US$13.38 million for the June quarter of 2020.
Also Read: Are you saving enough? Here’s how to build a retirement fund
Source - pixabay
Also Read: Seven stocks to go ex-dividend this week: Check the details here
OpGen, Inc.
OpGen stock retreated in after-hours after closing at a nearly 7% up in the regular session. The share volume was approximately 61,816,082. The stock surged on the news of FDA’s 510(k) clearance to market Acuitas® AMR Gene Panel. The company now plans to launch it commercially in the US in the Q4 of this year.
OPGN is a precision medicine company engaged in developing molecular information products and services to treat infectious diseases. The Gaithersburg, Maryland-situated company has a market capitalization of US$112 million. The company went public in 2015.
Its 52-week highest and lowest stock prices were US$4.37 and US$1.63, respectively.
Also Read: Five cybersecurity stocks that gave over 19% return YTD
For the quarter ended June 30, 2021, the company earned a revenue of US$0.812 million compared to US$1.19 million for the same quarter the previous year. The net loss was US$7.09 million or US$0.19 per share diluted compared to US$7.48 million or US$0.49 per share diluted for the June quarter of 2020.
The stock closed at US$2.76 with a share volume of US$625,254 on Oct 1. It gave a 44.12 percent return YTD.
On Monday, the company also announced the preliminary unaudited financials for Q3. The revenue was US$1.2 million, and cash reserves as of Sep 30, 2021, was about US$25.4 million.
Also Read: Top 10 crypto exchanges to explore as digital coins gain popularity
Bottomline
The NASDAQ biotechnology index gave around 2.91% return YTD. Overall, the health sector has been growing rapidly this year. However, investors must analyze the companies carefully before investing in the stock market.
